Literature DB >> 18483359

Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431).

Stephen R Moore1, Diane L Persons, Jeffrey A Sosman, Dolores Bobadilla, Victoria Bedell, David D Smith, Sandra R Wolman, Ralph J Tuthill, Jim Moon, Vernon K Sondak, Marilyn L Slovak.   

Abstract

PURPOSE: Gene copy number alteration (CNA) is common in malignant melanoma and is associated with tumor development and progression. The concordance between molecular cytogenetic techniques used to determine CNA has not been evaluated on a large set of loci in malignant melanoma. EXPERIMENTAL
DESIGN: A panel of 16 locus-specific fluorescence in situ hybridization (FISH) probes located on eight chromosomes was used to identify CNA in touch preparations of frozen tissue samples from 19 patients with metastatic melanoma (SWOG-9431). A subset (n = 11) was analyzed using bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH) of DNA isolated directly from touch-preparation slides.
RESULTS: By FISH, most samples showed loss near or at WISP3/6p21, CCND3/6q22, and CDKN2A/9p21 (>75% of samples tested). More than one third of CDKN2A/9p21 losses were biallelic. Gains of NEDD9/6p24, MET/7q31, and MYC/8q24 were common (57%, 47%, and 41%, respectively) and CNA events involving 9p21/7p12.3 and MET were frequently coincident, suggesting gain of the whole chromosome 7. Changes were confirmed by aCGH, which also uncovered many discreet regions of change, larger than a single BAC. Overlapping segments observed in >45% of samples included many of the loci analyzed in the FISH study, in addition to other WNT pathway members, and genes associated with TP53 pathways and DNA damage response, repair, and stability.
CONCLUSIONS: This study outlines a set of CNAs at the gene and regional level, using FISH and aCGH, which may provide a benchmark for future studies and may be important in selection of individual therapy for patients with metastatic malignant melanoma.

Entities:  

Mesh:

Year:  2008        PMID: 18483359     DOI: 10.1158/1078-0432.CCR-07-4068

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Authors:  Matthew W Vanbrocklin; James P Robinson; Todd Whitwam; Adam R Guilbeault; Julie Koeman; Pamela J Swiatek; George F Vande Woude; Joseph D Khoury; Sheri L Holmen
Journal:  Pigment Cell Melanoma Res       Date:  2009-04-29       Impact factor: 4.693

4.  Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Authors:  Elisabetta Vergani; Viviana Vallacchi; Simona Frigerio; Paola Deho; Piera Mondellini; Paola Perego; Giuliana Cassinelli; Cinzia Lanzi; Maria Adele Testi; Licia Rivoltini; Italia Bongarzone; Monica Rodolfo
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

5.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.

Authors:  Anjali S Advani; Holly M Gundacker; Olga Sala-Torra; Jerald P Radich; Raymond Lai; Marilyn L Slovak; Jeffrey E Lancet; Steve E Coutre; Robert K Stuart; Martha P Mims; Patrick J Stiff; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2010-12       Impact factor: 6.998

6.  Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.

Authors:  Marilyn L Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B Estrine; Norma J Nowak; Maria L Delioukina; Lawrence M Weiss; David D Smith; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 7.  Malignant melanoma and melanocortin 1 receptor.

Authors:  A A Rosenkranz; T A Slastnikova; M O Durymanov; A S Sobolev
Journal:  Biochemistry (Mosc)       Date:  2013-11       Impact factor: 2.487

Review 8.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

Review 9.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15

10.  Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment.

Authors:  Frances P Noonan; M Raza Zaidi; Agnieszka Wolnicka-Glubisz; Miriam R Anver; Jesse Bahn; Albert Wielgus; Jean Cadet; Thierry Douki; Stephane Mouret; Margaret A Tucker; Anastas Popratiloff; Glenn Merlino; Edward C De Fabo
Journal:  Nat Commun       Date:  2012-06-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.